261 related articles for article (PubMed ID: 26833657)
1. The Impact of Alemtuzumab and Basiliximab Induction on Patient Survival and Time to Bronchiolitis Obliterans Syndrome in Double Lung Transplantation Recipients.
Furuya Y; Jayarajan SN; Taghavi S; Cordova FC; Patel N; Shiose A; Leotta E; Criner GJ; Guy TS; Wheatley GH; Kaiser LR; Toyoda Y
Am J Transplant; 2016 Aug; 16(8):2334-41. PubMed ID: 26833657
[TBL] [Abstract][Full Text] [Related]
2. Rescue alemtuzumab for refractory acute cellular rejection and bronchiolitis obliterans syndrome after lung transplantation.
Ensor CR; Rihtarchik LC; Morrell MR; Hayanga JW; Lichvar AB; Pilewski JM; Wisniewski S; Johnson BA; D'Cunha J; Zeevi A; McDyer JF
Clin Transplant; 2017 Apr; 31(4):. PubMed ID: 28008661
[TBL] [Abstract][Full Text] [Related]
3. Five-year outcomes with alemtuzumab induction after lung transplantation.
Shyu S; Dew MA; Pilewski JM; DeVito Dabbs AJ; Zaldonis DB; Studer SM; Crespo MM; Toyoda Y; Bermudez CA; McCurry KR
J Heart Lung Transplant; 2011 Jul; 30(7):743-54. PubMed ID: 21420318
[TBL] [Abstract][Full Text] [Related]
4. A comparison of basiliximab and anti-thymocyte globulin as induction agents after lung transplantation.
Hachem RR; Chakinala MM; Yusen RD; Lynch JP; Aloush AA; Patterson GA; Trulock EP
J Heart Lung Transplant; 2005 Sep; 24(9):1320-6. PubMed ID: 16143251
[TBL] [Abstract][Full Text] [Related]
5. Alemtuzumab in the treatment of refractory acute rejection and bronchiolitis obliterans syndrome after human lung transplantation.
Reams BD; Musselwhite LW; Zaas DW; Steele MP; Garantziotis S; Eu PC; Snyder LD; Curl J; Lin SS; Davis RD; Palmer SM
Am J Transplant; 2007 Dec; 7(12):2802-8. PubMed ID: 17924993
[TBL] [Abstract][Full Text] [Related]
6. Antibody induction therapy for lung transplant recipients.
Penninga L; Møller CH; Penninga EI; Iversen M; Gluud C; Steinbrüchel DA
Cochrane Database Syst Rev; 2013 Nov; 2013(11):CD008927. PubMed ID: 24282128
[TBL] [Abstract][Full Text] [Related]
7. Induction therapy in lung transplantation: A contemporary analysis of trends and outcomes.
Shagabayeva L; Osho AA; Moonsamy P; Mohan N; Li SS; Wolfe S; Langer NB; Funamoto M; Villavicencio MA
Clin Transplant; 2022 Nov; 36(11):e14782. PubMed ID: 35848518
[TBL] [Abstract][Full Text] [Related]
8. Influence of human leukocyte antigen mismatching on bronchiolitis obliterans syndrome in lung transplantation.
Hayes D; Black SM; Tobias JD; Kopp BT; Kirkby SE; Mansour HM; Whitson BA
J Heart Lung Transplant; 2016 Feb; 35(2):186-94. PubMed ID: 26496787
[TBL] [Abstract][Full Text] [Related]
9. Induction Therapy for Lung Transplantation in COPD: Analysis of the UNOS Registry.
Duffy JS; Tumin D; Pope-Harman A; Whitson BA; Higgins RS; Hayes D
COPD; 2016 Oct; 13(5):647-52. PubMed ID: 26829054
[TBL] [Abstract][Full Text] [Related]
10. Effects of induction immunosuppression regimen on acute rejection, bronchiolitis obliterans, and survival after lung transplantation.
Ailawadi G; Smith PW; Oka T; Wang H; Kozower BD; Daniel TM; Kron IL; Jones DR
J Thorac Cardiovasc Surg; 2008 Mar; 135(3):594-602. PubMed ID: 18329476
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of Basiliximab and Alemtuzumab induction therapies in blood type A2-to-B kidney transplantation: Impact on kidney function and de novo donor-specific HLA antibodies.
Hanouneh T; Attieh RM; Craver E; Jebrini A; Elrefaei M; Jarmi T
Transpl Immunol; 2023 Dec; 81():101958. PubMed ID: 37949378
[TBL] [Abstract][Full Text] [Related]
12. Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation.
Hachem RR; Yusen RD; Meyers BF; Aloush AA; Mohanakumar T; Patterson GA; Trulock EP
J Heart Lung Transplant; 2010 Sep; 29(9):973-80. PubMed ID: 20558084
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes following alemtuzumab induction in lung transplantation.
Wehman B; Griffith BP; Balwan A; Kon ZN; Suffredini DA; Evans C; Garcia JP; Iacono A
Heart Surg Forum; 2013 Oct; 16(5):E252-6. PubMed ID: 24217238
[TBL] [Abstract][Full Text] [Related]
14. Donor factors are associated with bronchiolitis obliterans syndrome after lung transplantation.
Hennessy SA; Hranjec T; Swenson BR; Kozower BD; Jones DR; Ailawadi G; Kron IL; Lau CL
Ann Thorac Surg; 2010 May; 89(5):1555-62. PubMed ID: 20417777
[TBL] [Abstract][Full Text] [Related]
15. Quantitative chest CT for subtyping chronic lung allograft dysfunction and its association with survival.
Horie M; Salazar P; Saito T; Binnie M; Brock K; Yasufuku K; Azad S; Keshavjee S; Martinu T; Paul N
Clin Transplant; 2018 May; 32(5):e13233. PubMed ID: 29637624
[TBL] [Abstract][Full Text] [Related]
16. Steroid maintenance in repeat kidney transplantation: influence of induction agents on outcomes.
Sureshkumar KK; Hussain SM; Nashar K; Marcus RJ
Saudi J Kidney Dis Transpl; 2014 Jul; 25(4):741-9. PubMed ID: 24969182
[TBL] [Abstract][Full Text] [Related]
17. Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.
; Haynes R; Harden P; Judge P; Blackwell L; Emberson J; Landray MJ; Baigent C; Friend PJ
Lancet; 2014 Nov; 384(9955):1684-90. PubMed ID: 25078310
[TBL] [Abstract][Full Text] [Related]
18. Induction therapy in renal transplant recipients: how convincing is the current evidence?
Wagner SJ; Brennan DC
Drugs; 2012 Mar; 72(5):671-83. PubMed ID: 22439670
[TBL] [Abstract][Full Text] [Related]
19. Differential rates of ischemic cholangiopathy and graft survival associated with induction therapy in DCD liver transplantation.
Halldorson JB; Bakthavatsalam R; Montenovo M; Dick A; Rayhill S; Perkins J; Reyes J
Am J Transplant; 2015 Jan; 15(1):251-8. PubMed ID: 25534449
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Alemtuzumab Versus Basiliximab Induction Therapy in Elderly Kidney Transplant Recipients: A Single-Center Experience.
Yakubu I; Ravichandran B; Sparkes T; Barth RN; Haririan A; Masters B
J Pharm Pract; 2021 Apr; 34(2):199-206. PubMed ID: 31315501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
